Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan

Journal of Viral Hepatitis

Volumn 24, Issue 6, 2017, Pages 472-476

  Toyoda, H ^a   Tada, T ^a   Takaguchi, K ^b   Senoh, T ^b   Shimada, N ^c   Hiraoka, A ^d   Michitaka, K ^d   Ishikawa, T ^e   Kumada, T ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Department of Neurosurgery   (Japan)

^d EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e Saiseikai Niigata Daini Hospital   (Japan)

Author keywords

chronic hepatitis C; hepatocellular carcinoma; IFN based therapy; IFN free therapy; risk score; sustained virologic response

Indexed keywords

ALPHA FETOPROTEIN; ASUNAPREVIR; DACLATASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; INTERFERON;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; INTERFERON BASED ANTIVIRAL THERAPY; INTERFERON FREE ANTIVIRAL THERAPY; JAPAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; VIRAL CLEARANCE; CLINICAL TRIAL; COMPLICATION; INCIDENCE; LIVER TUMOR; MULTICENTER STUDY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK ASSESSMENT; SUSTAINED VIROLOGIC RESPONSE;

EID: 85019582659     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12665     Document Type: Article

References (17)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095–2100.
2. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–1130.
3. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129:94–99.
4. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–181.
5. Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective multicenter study. J Hepatol. 2013;58:495–501.
6. Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int. 2004;24:603–610.
7. Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol. 2005;20:752–758.
8. Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148–156.
9. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–1622.
10. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–236.
11. Toyoda H, Kumada T, Tada T, et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015;30:1183–1189.
12. El-Serag HB, Kanwal F, Richardson P, DeBakey ME. Risk of hepatocellular carcinoma after sustained virologic response in veterans with HCV-infection. Hepatology. 2016;64:130–137.
13. Chang KC, Hung CH, Lu SN, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012;67:2766–2772.
14. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.
15. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology. 2007;46:32–36.
16. Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol. 2016;65:856–858.
17. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol. 2016;65:727–733.